News Amgen Inc. Sao Paulo

Equities

AMGN34

BRAMGNBDR004

Market Closed - Sao Paulo Other stock markets 20:29:55 24/05/2024 BST			5-day change	1st Jan Change
56.88 ^BRL	+0.21%		-2.02%	+13.87%

05-22	Sandoz: Marketing authorization for Wyost and Jubbonti in the EU	CF
05-22	Roche Gets US FDA Breakthrough Designation For Lipoprotein(a) Test	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Amgen : An Underrecognized Risk Factor for Heart Disease	05-23	PU
Improving treatment responses to solid tumours with trispecific TCEs	05-23	AQ
Amgen : From the Office to the Lab, Amgen Uses AI Tools to Unlock Innovation	05-22	PU
Sandoz: Marketing authorization for Wyost and Jubbonti in the EU	05-22	CF
Roche Gets US FDA Breakthrough Designation For Lipoprotein(a) Test	05-22	MT
Amgen : Actress and Producer Gina Torres Urges Hispanic Americans to Prioritize Cholesterol Care	05-21	PU
Amgen : At Milken Global Conference, Bradway Calls for Protecting U.S. Policy Ecosystem That Fosters Innovation	05-20	PU
Driving Long-Term Growth: IMDELLTRA™ Approval and Information Update Presentation	05-20	PU
Transcript : Amgen Inc. - Special Call	05-20
Astrazeneca - New data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease	05-20	AQ
AMGEN - NEW DATA PRESENTED AT ATS 2024 SHOW THE POTENTIAL OF TEZSPIRE TO HELP PATIENTS LIVING WITH COPD	05-20	AQ
HSBC Adjusts Price Target on Amgen to $356 From $322	05-20	MT
Amgen and AstraZeneca's Lung Disease Drug Study Reports Mixed Results	05-20	MT
Amgen And Sandoz Settle Denosumab BPCIA Litigation	05-20	AQ
Amgen Announces the Results of the Phase 2a COURSE Trial Evaluating Tezspire® (Tezepelumab-Ekko) in People with Moderate to Very Severe Chronic Obstructive Pulmonary Disease	05-19	CI
US FDA approves Amgen drug for small cell lung cancer	05-17	RE
Amgen : Expanding Innovation in BiTE® Technology for Patients with Extensive Stage Small Cell Lung Cancer (ES SCLC)	05-17	PU
FDA Approves Amgen's IMDELLTRA?? (Tarlatamab-Llle) for the Treatment of Adult Patients with Extensive-Stage Small Cell Lung Cancer	05-16	CI
Amgen Gets FDA Approval for Small-Cell Lung-Cancer Treatment	05-16	DJ
Amgen's Imdelltra Gets US FDA Accelerated Approval for Drug to Treat Extensive Stage Small Cell Lung Cancer	05-16	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Amgen Inc. Sao Paulo

Equities

AMGN34

BRAMGNBDR004

Summary

Filters